8:58 AM
 | 
Jun 07, 2017
 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular; hematology

INDICATION: Atherosclerosis; hematology

Patient sample and mouse studies suggest inhibiting S100A9 could help treat diabetes-related atherosclerosis and thrombocytosis. In plasma samples from Type II diabetes patients, levels of S100A9 were higher than in samples from healthy volunteers. In a mouse model of diabetes-induced thrombocytosis, the S100A9-targeting small molecule paquinimod or systemic or...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >